Testing zelpultide alfa for preterm babies at risk of lung disease
Part of Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a medicine called zelpultide alfa in very premature babies who are at high risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The goal is to see if it can help prevent or lessen lung problems compared to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Born between 22 weeks and 27 weeks 6 days of pregnancy
- Received at least one dose of standard lung surfactant after birth
- On a breathing machine with a tube in the windpipe
- Able to get first dose of study drug within 96 hours of birth and within 48 hours of starting the breathing machine
- Birth weight between 400 grams and 1,500 grams
- No major birth defects of the heart or lungs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
This study looks at babies born very early who have severe lung disease (grade 3 BPD) and still need a breathing machine. Researchers will use tests to understand their lung problems better, which may help guide their care.
This trial tests a standardized, team-agreed discharge plan to help preterm babies with lung disease (often called BPD) leave the hospital safely. It may help by making the discharge process more consistent, especially for babies going home on breathing support like oxygen.
Hear when a new Bronchopulmonary Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.